SINONASAL UNDIFFERENTIATED CARCINOMA
Clinical trials for SINONASAL UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SINONASAL UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for SINONASAL UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for rare sinus cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal tumors more effectively and with fewer side effects. About 28 adults with a rare, aggressive sinus cancer will receive the combination, then …
Matched conditions: SINONASAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
Radiation plus targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive …
Matched conditions: SINONASAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 08, 2026 12:03 UTC